[Para 1: The Lead]

Broadridge Financial Solutions Inc. (BRDS) reported a 15% increase in second quarter 2026 earnings to $320 million, surpassing analysts' estimates of $285 million. The company's stock symbol is BRDS. This financial breakthrough is attributed to robust growth in its advisory and technology segments, driving a 12% revenue increase to $1.2 billion.

[Para 2-3: Supporting details & Context]

As of the publication date, 2026-02-03, the company's stock has seen an upward trend, reflecting investors' confidence in its financial performance. The earnings per share (EPS) rose to $2.00 from $1.75 in the same period last year. CEO, Jim Ryan, stated, "Our strong performance in Q2 is a testament to our strategic focus on innovation and client-centric solutions." The company's dividend per share was also increased by 10% to $0.55, reinforcing its commitment to shareholder value.

[Para 1: The Lead]

Pfizer, the American pharmaceutical giant (PFE-US), exceeded market expectations for its Q4 2025 earnings, bolstered by strong performance from mature products. Despite a significant drop in COVID-19 vaccine and oral drug sales, the company reported a Q4 revenue of $17.56 billion, surpassing the market consensus of $16.95 billion. Adjusted earnings per share stood at $0.66, exceeding analyst estimates. However, Pfizer maintained a cautious outlook for 2026, citing ongoing challenges from patent expirations and pricing pressures.

[Para 2-3: Supporting details & Context]

Pfizer's success was driven by robust sales of its mature products, including Eliquis at $2 billion, Prevnar at $1.7 billion, and Vyndaqel meeting market expectations. The RSV vaccine Abrysvo also outperformed with sales of $1.03 billion, a significant increase from market forecasts. However, COVID-19 vaccine sales fell to $2.3 billion, down 30% year-over-year, and Paxlovid sales were $218 million, a 67% decline, below market expectations. Pfizer expects COVID-19 product sales to continue declining, with a further $1.5 billion in sales reductions in 2026 due to patent expirations and increased competition. Additionally, pricing policies and potential impacts on future medical insurance negotiations will further pressure profitability.

Pfizer's hope for growth lies in its new drug development and acquisition strategies, particularly in obesity drugs. The company's first interim data on Metsera's weight loss drug showed a 12.3% weight loss in 28 weeks. However, market reaction has been cautious due to limited data on safety and comparative efficacy. Pfizer aims to launch approximately 20 late-stage clinical trials in 2026, focusing on obesity drugs for potential 2028 approval. The company also plans to cut $7.7 billion in costs by 2027 to manage the transition pressures following the wind-down of COVID-19 profits.

[Para 1: The Lead] Madison Square Garden Entertainment Corp. (MSGE) reported a fiscal second-quarter net income of $92.7 million, missing Wall Street expectations of $2.35 per share, instead earning $1.94 per share. Revenue of $459.9 million surpassed forecasts, indicating a 1.1% increase over the previous quarter.

[Para 2-3: Supporting details & Context] MSGE's financial figures reflect strong performance in its live entertainment segment. The company's ability to exceed revenue expectations despite earnings falling short of analyst predictions suggests resilience in its core business. Analysts are now adjusting their forecasts in light of this outcome, with attention on how MSGE can sustain its financial momentum in an increasingly competitive market.

[Para 1: The Lead] Merck (NYSE:MRK) surpassed Wall Street revenue forecasts in Q4 CY2025, reporting sales of $16.4 billion, up 5% year-over-year. The company's non-GAAP earnings per share (EPS) of $2.04 surpassed analysts' estimates by 1.5%. Despite missing full-year revenue guidance and EPS projections, Merck's Q4 performance indicates resilience and potential for continued growth.

[Para 2-3: Supporting details & Context] Merck's full-year revenue guidance of $66.25 billion was 2% below analyst expectations. However, its non-GAAP profit of $2.04 per share was 1.5% above consensus. The company's strong Q4 performance, driven by its oncology and infectious disease therapies, highlights its competitive edge. Merck's efficiency in revenue generation and profitability, evidenced by a 6.2 percentage point increase in operating margin over the last five years, positions it for sustained growth. Despite the stock's slight dip post-earnings, Merck's Q4 results suggest a strong financial foundation and potential for future earnings.

[Para 1: The Lead] Marzetti Company (MZTI) announced its fiscal second quarter earnings on Tuesday, showcasing a significant profit of $59.1 million. The company's earnings per share stood at $2.15, adjusted for non-recurring costs, marking a slight increase to $2.20. This financial performance highlights strong market demand for Marzetti's specialty food products.

[Para 2-3: Supporting details & Context] Revenue for the quarter reached $518 million, reflecting a steady growth in sales. MZTI's financial success is underpinned by its strategic focus on expanding its product portfolio and enhancing brand presence. The company's fiscal health and market leadership are expected to drive continued growth in the upcoming quarters.

[Para 1: The Lead] Hubbell Inc. (HUBB) announced its fourth-quarter earnings on Tuesday, surpassing Wall Street forecasts. The company reported a net income of $224.2 million, equating to $4.19 per share, after adjusting for one-time gains and costs. This is $0.04 more than the average analyst estimate of $4.70 per share.

[Para 2-3: Supporting details & Context] Revenue for the quarter stood at $1.49 billion, meeting market expectations. For the fiscal year, Hubbell reported a profit of $887.1 million, or $16.54 per share, on revenues of $5.84 billion. The company has set a full-year earnings guidance of $19.15 to $19.85 per share, indicating confidence in its growth trajectory. The strong financial performance reflects robust demand in its electrical products segment.

[Para 1: The Lead] BellRing Brands (BRBR) exceeded Q4 CY2025 earnings and revenue expectations, reporting a non-GAAP profit of $0.37 per share, 16.7% above consensus. Revenue stood at $537.3 million, flat year-over-year. The company guided full-year revenue at $2.44 billion, 0.9% above estimates.

[Para 2-3: Supporting details & Context] BellRing, spun out of Post Holdings in 2019, saw its annualized revenue growth of 17.6% over the past three years, driven by volume expansion. Despite Q4 sales volumes being flat, the company's organic revenue growth outperformed Wall Street by a wide margin. Analysts forecast 5.2% revenue growth over the next 12 months, indicating market optimism. BellRing's gross margin missed expectations, and full-year revenue guidance was slightly reduced. The stock closed flat at $24.39 post-results.

[Para 1: The Lead]

Palantir Technologies Inc. (NYSE: PLTR) shares surged in after-hours trading following a strong Q4 earnings report, beating analysts' estimates. PayPal Holdings Inc. (NASDAQ: PYPL) saw its stock plunge, while Pepsico Inc. (NASDAQ: PEP) slipped. The market reaction highlights the divergence in financial performance among tech giants.

[Para 2-3: Supporting details & Context]

Palantir reported a 20% increase in revenue to $490 million, surpassing expectations by 15%. The company's net loss narrowed to $10 million, down from $30 million a year ago. PayPal's stock fell 12% after reporting a 5% decline in Q4 revenue to $7.5 billion, below market forecasts. Pepsico's earnings per share missed estimates by 2%, leading to a 3% drop in its stock price. These moves reflect the volatility and sensitivity of the market to earnings reports.

[Para 1: The Lead]

India's Supreme Court has ruled that WhatsApp cannot monitor its users without explicit consent, a significant legal victory for privacy rights. The decision, effective 2026-02-04, mandates that the messaging app must obtain user consent for any data collection or monitoring activities. This ruling is expected to have a broad impact on global privacy regulations, particularly in regions with stringent data protection laws.

[Para 2-3: Supporting details & Context]

The court's decision is based on the interpretation of India's Information Technology Act and the right to privacy as a fundamental human right. It follows a series of legal challenges and concerns over data privacy and surveillance. The ruling could lead to stricter enforcement of privacy laws and potentially influence similar legal actions in other countries. Financial markets reacted with cautious optimism, as the decision may strengthen consumer trust and privacy-focused investment opportunities.

[Para 1: The Lead] SpaceX, under CEO Elon Musk, successfully launches its much-anticipated mega-IPO, significantly impacting the stock market. Shares of TSLA (Tesla Inc.) surge 12% post-IPO, reflecting investor confidence in Musk's ventures. The IPO, priced at $20 per share, was oversubscribed by 10 times, raising $2 billion.

[Para 2-3: Supporting details & Context] The IPO, a landmark event in the aerospace and automotive sectors, is the largest for a private company in history. SpaceX, known for its advancements in space exploration and satellite internet, now seeks to expand its operations and fund future projects. The stock's strong performance is attributed to the company's recent achievements, including the successful launch of Starlink satellites and the ongoing development of the Starship spacecraft. Investors are optimistic about SpaceX's future growth and market dominance.

[Para 1: The Lead]

Merck (MRK-US), the American pharmaceutical giant, reported its Q4 2025 earnings on Tuesday, February 3, 2026. Despite strong sales of its cancer drug Keytruda and several new drugs exceeding market expectations, Merck issued a cautious outlook for 2026, projecting lower revenues and adjusted earnings per share than market consensus. The company cited ongoing pressure from the Gardasil vaccine in China and patent expirations on several old drugs as key factors.

[Para 2-3: Supporting details & Context]

Merck forecasted 2026 revenues between $65.5 billion and $67 billion, below the market average of $67.6 billion. Adjusted earnings per share were expected to range from $5 to $5.15, short of market estimates. This guidance impacted Merck's pre-market stock performance, with the stock down 0.77% to $112.50.

Merck's cautious guidance is primarily due to two major factors. Firstly, the Gardasil vaccine's sales in China are weaker than expected, with Merck ceasing shipments to China and not including any assumptions for Chinese sales in its 2026 forecast. The vaccine's sales in Q4 2025 were $1.03 billion, down over 30% year-over-year, affected by economic weakness in China, anti-corruption measures impacting the market, and the emergence of low-cost generic vaccines. Additionally, several old drugs are facing patent expirations and increased competition from generic drugs, which is expected to impact long-term growth.

Merck's Q4 2025 performance was bolstered by Keytruda and new drugs. Keytruda sales reached $8.37 billion, up 7% year-over-year, driven by expanded indications for early-stage cancers and growing demand for metastatic cancer treatments. The company's new drug Winrevair saw sales of $467 million in Q4 2025, exceeding market expectations, reflecting increased usage in the U.S. and early market launches in certain overseas markets. Ohtuvayre also performed better than expected, indicating that recent acquisitions are contributing to operational success.

Merck is restructuring to adapt to these changes, pursuing acquisitions and cost control simultaneously. The company has initiated a $3 billion cost reduction plan through 2027 and is preparing for the potential revenue gap after Keytruda's patent expiration in 2028. Merck has spent approximately $10 billion on acquisitions of Verona Pharma and Cidara Therapeutics to strengthen its respiratory disease and infectious disease product lines. The company plans to focus on oncology, cardiovascular metabolism, and immunology, continuously evaluating potential acquisition opportunities. Merck's agreement with the Trump administration on drug pricing, which resulted in a three-year tariff exemption, has been factored into its 2026 guidance, with the company stating the impact is within a 'manageable range.'

In summary, Merck faces short-term pressures from vaccine sales and patent expirations but remains supported by Keytruda and new drugs. The market will closely watch how Merck's product transition and acquisition strategy will smoothly transition to long-term growth.

Bitcoin stalled Tuesday near $78,500 after a weak rebound from Monday’s 10-month low of $74,541, with options market data reflecting persistent trader caution. Despite a brief intraday rally above $79,100 in early Asian trading, the cryptocurrency gave up gains and remained under pressure as of February 3, 2026.

Deribit data shows concentrated put options at the $75,000 strike, marking it as a critical support level; a weekly close below this threshold could trigger a slide toward $69,000–$70,000, according to FalconX’s Sean McNulty. Bitcoin’s implied volatility held elevated at 48.8%, while perpetual futures funding rates turned negative—the lowest since August 2024—indicating short sellers dominate the market. “Markets got over their skis selling risk assets,” said STS Digital’s Jeff Anderson, noting a temporary stabilization after the sharp selloff.

Manhattan Associates (MANH) exceeded Q4 expectations on February 3, 2026, driven by strong cloud revenue growth and a rebound in services. CEO Eric Clark said over 75% of new cloud bookings came from net new customers, citing accelerated migrations and expansion beyond retail.

Analysts pressed management on the monetization timeline for new AI agent features, progress converting legacy on-premise clients to cloud subscriptions, and how increased sales and services investments may affect margins. The company’s stock fell to $150.57 from $169.73 pre-earnings, raising questions about near-term valuation despite robust cloud momentum and improved implementation efficiency.

Commvault (CVLT) stock plunged nearly 32% to $88.23 on February 3, 2026, despite reporting record new subscription customers and strong top-line growth in Q4, as a higher mix of lower-priced SaaS deals diluted annual recurring revenue (ARR) growth. CEO Sanjay Mirchandani highlighted the company’s best-ever quarter for new term software customers and robust adoption of cloud-native offerings like Clumio, while CFO Daniel Abrahamson cited elongated deal cycles in large enterprises and lower average selling prices from SaaS conversions as headwinds to ARR.

Analysts pressed management on the sustainability of SaaS-driven growth and its margin impact. Investors will now monitor Unity platform adoption, SaaS ARR trajectory, cost optimization efficacy, and customer feedback on hybrid cloud and cyber resilience integrations. The stock had traded as high as $129.36 before the earnings release.

Stride Inc. (NYSE: LRN) shares rose to $87.88 on February 3, 2026, up from $72.43 pre-earnings, after reporting Q4 results driven by disciplined product launches in the U.S. generics market and strategic exits from low-margin businesses. CEO Badri cited consistent execution and strong service levels for maintaining premium positioning amid competition.

Analysts pressed management on three key fronts: the pace of new filings in controlled substances and complex dosage forms, sustainability of double-digit growth in regulated international markets, and progress in operating leverage and free cash flow conversion. The company reported crossing key revenue thresholds outside the U.S., though scale remains below domestic levels. Regulatory shifts and competitive pressures were flagged as critical variables for Stride’s long-term strategy.

UMB Financial Corp. (UMBF) reported fourth-quarter 2025 results that beat Wall Street’s revenue and adjusted earnings expectations, driven by strong commercial loan growth, successful integration of Heartland Financial, and momentum in fee-based businesses like trust and securities processing. Despite the beat, shares rose only modestly to $128.05 from $124.86 pre-earnings on February 3, 2026.

CEO Mariner Kemper emphasized scale-building, profitable balance sheet growth, and sustained asset quality. Analysts focused on whether Heartland’s integration will drive incremental loan and fee income, if above-peer commercial lending momentum is sustainable, and how expense discipline holds as merger-related cost synergies normalize. Continued expansion in fee-based services and stable credit metrics remain key execution benchmarks.

WesBanco (WSBC) shares fell over 3.5% on February 3, 2026, after reporting Q4 results that met revenue expectations but missed non-GAAP earnings per share. Management cited successful integration of Premier Financial, fully funded loan growth via strong deposits, and cost discipline as key drivers, despite elevated commercial real estate (CRE) loan payoffs.

CFO Daniel Weiss noted higher expenses stemmed from the enlarged balance sheet and acquisition costs, while highlighting margin expansion and funding cost optimization. Analysts pressed on the sustainability of organic loan growth amid CRE runoff, realization of cost savings from branch closures, and progress in new markets like healthcare lending and Southeast expansion. The stock traded at $36.15 as of the report date.

OpenAI and NVIDIA (NVDA-US) are navigating a strained strategic relationship as artificial intelligence shifts from model training to inference, where speed and efficiency are critical. While NVIDIA dominates AI training with its GPUs, its reliance on external memory creates bottlenecks in high-speed inference tasks—particularly for OpenAI’s latency-sensitive Codex coding product.

OpenAI is now evaluating alternatives, including chips from Cerebras and AMD, aiming to internalize roughly 10% of its inference workload. This pivot has stalled NVIDIA’s planned investment in OpenAI, with negotiations deadlocked for months due to shifting hardware requirements. NVIDIA countered by securing an exclusive licensing deal with inference startup Groq, blocking a potential OpenAI partnership. Despite public reassurances from CEOs Jensen Huang and Sam Altman affirming mutual support and ongoing collaboration, the underlying tension reflects a deeper realignment in the AI infrastructure race.

MicroStrategy (MSTR-US) faces mounting scrutiny as Bitcoin briefly fell below its average acquisition cost of $76,052 on February 2, 2026, challenging the sustainability of its "equity-for-Bitcoin" strategy. The company holds over 713,000 BTC, valued at approximately $53.2 billion, against a total investment of $54.2 billion, resulting in a paper loss.

Despite the dip, MicroStrategy remains financially stable with no margin calls or forced sales, backed by a $2.25 billion cash buffer from recent equity offerings. However, its core strategy—issuing shares when stock trades above Bitcoin’s book value per share—has weakened as its share price has dropped ~70% from peaks, erasing the equity premium needed to fund further purchases without excessive dilution. The firm bought $75.3 million in Bitcoin between January 26 and February 1.

With MSTR’s market cap now nearly equal to its Bitcoin holdings, any BTC volatility directly amplifies investor sentiment toward CEO Michael Saylor’s high-risk bet. Analysts warn that without a sustained Bitcoin rally or renewed equity demand, the model’s viability may falter.

WuXi Biologics (2269.HK) shares climbed on February 3, 2026, after announcing a strategic partnership with Vertex Pharmaceuticals (VRTX) to develop a T-cell engager for autoimmune diseases. The collaboration grants Vertex exclusive global rights to the candidate therapy, with WuXi Biologics eligible for up to $1.2 billion in milestone payments plus tiered royalties.

Under the agreement, WuXi Biologics will lead early-stage research and preclinical development, while Vertex assumes responsibility for clinical trials and commercialization. The deal marks Vertex’s latest move to expand beyond its core cystic fibrosis franchise into immunology, leveraging WuXi’s proprietary technology platform for novel biologics.